Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Depreciation & Amortization (CF) (2020 - 2025)

Treace Medical Concepts' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 25.53% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $10.6 million, up 26.18%, while the annual FY2025 figure was $10.6 million, 26.18% up from the prior year.
  • Depreciation & Amortization (CF) reached $2.8 million in Q4 2025 per TMCI's latest filing, up from $2.8 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.8 million in Q4 2025 to a low of $100000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.4 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 75.0% in 2021, then surged 300.0% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $285000.0 in 2021, then skyrocketed by 221.75% to $917000.0 in 2022, then skyrocketed by 92.91% to $1.8 million in 2023, then increased by 26.46% to $2.2 million in 2024, then increased by 25.53% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Depreciation & Amortization (CF) are $2.8 million (Q4 2025), $2.8 million (Q3 2025), and $2.6 million (Q2 2025).